FILE PHOTO: Pascal Soriot, chief executive officer of pharmaceutical company AstraZeneca, attends an interview with Reuters in Shanghai, China November 4, 2019. Picture taken November 4, 2019. REUTERS/Brenda Goh
LONDON - AstraZeneca’s chief executive officer Pascal Soriot said on Monday that the lower first dose of its experimental COVID-19 vaccine meant more people can be vaccinated more quickly, as the British drugmaker unveiled interim late-stage trial results.The British drugmaker said on Monday its vaccine for the novel coronavirus could be around 90% effective without any serious side effects.
The vaccine developed by Oxford University was most effective when it was administered as a half dose followed by a full dose at least one month apart, rather than as two full doses at least one month apart. Reporting by Kate Kelland, Guy Faulconbridge and Kate Holton; Writing by Josephine Mason; Editing by Edmund Blair
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.